Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. raised its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 100.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 89,618 shares of the company’s stock after acquiring an additional 44,893 shares during the quarter. Principal Financial Group Inc. owned approximately 0.06% of Xeris Biopharma worth $198,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Tower Research Capital LLC TRC boosted its position in shares of Xeris Biopharma by 53.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 27,848 shares of the company’s stock valued at $65,000 after purchasing an additional 9,733 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Xeris Biopharma by 66.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 26,516 shares of the company’s stock valued at $59,000 after purchasing an additional 10,543 shares during the period. SG Americas Securities LLC boosted its position in shares of Xeris Biopharma by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 33,777 shares of the company’s stock valued at $79,000 after purchasing an additional 15,414 shares during the period. Quarry LP acquired a new stake in shares of Xeris Biopharma in the 4th quarter valued at about $47,000. Finally, Diversified Trust Co boosted its position in shares of Xeris Biopharma by 12.9% in the 1st quarter. Diversified Trust Co now owns 175,741 shares of the company’s stock valued at $388,000 after purchasing an additional 20,091 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on XERS. Piper Sandler reissued an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of Xeris Biopharma in a research report on Friday, May 10th. Oppenheimer started coverage on Xeris Biopharma in a research report on Thursday, March 28th. They set an “outperform” rating and a $5.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Xeris Biopharma in a research report on Friday, May 31st.

Xeris Biopharma Stock Up 0.9 %

Xeris Biopharma stock opened at $2.13 on Tuesday. The stock has a 50 day moving average of $2.08 and a two-hundred day moving average of $2.29. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.46 and a twelve month high of $3.26.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $40.64 million for the quarter, compared to analysts’ expectations of $41.56 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 37.58%. Analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.